-
Mashup Score: 0Silent Cerebral Infarction During iTTP Can Affect Cognition | ASH Clinical News | American Society of Hematology - 9 month(s) ago
Lara C. Pullen, PhD, is a freelance medical writer in Chicago. Silent cerebral infarction (SCI) refers to the often-incidental finding of brain infarction in the absence of overt neurologic deficits. Magnetic resonance imaging (MRI) evidence suggests that not only are such brain infarctions com mon in survivors of immune thrombotic thrombocytopenia purpura (iTTP), but they are also strongly associated with impaired cognition. Shruti Chaturvedi, MBBS, MS, of Johns Hopkins University in Baltimore, and
Source: ashpublications.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Caplacizumab Reduces Exacerbations and Refractoriness in Real-World iTTP | ASH Clinical News | American Society of Hematology - 1 year(s) ago
Skip Nav Destination October 27, 2022 Treatment with caplacizumab was associated with significant reductions in exacerbations and refractoriness in a real-world immune thrombotic thrombocytopenic purpura (iTTP) population compared…
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Patient Race Linked to Relapse Risk and Rituximab Response in iTTP | ASH Clinical News | American Society of Hematology - 2 year(s) ago
Skip Nav Destination September 26, 2022 Race affects overall relapse risk and response to rituximab in immune-mediated thrombotic thrombocytopenic purpura (iTTP), according to a study published in Blood. The study showed that Black patients with…
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
Skip Nav Destination May 31, 2022 Vaccination against SARS-CoV-2 does not appear to increase the risk of de novo immune thrombotic thrombocytopenic purpura (iTTP), according to a report published in Blood.1…
Source: ashpublications.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Modified Caplacizumab Dosing for iTTP Offers Cost Savings, More Individualized Therapy | ASH Clinical News | American Society of Hematology - 2 year(s) ago
Skip Nav Destination April 27, 2022 The extension of caplacizumab application intervals from daily to alternate-day dosing may be safely considered after three to four weeks of daily treatment in selected…
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 43.18 Social Media and News with Dr. Benjamin Mazer & Caplacizumab for TTP with Dr. Tem Bendapudi - 3 year(s) ago
This week we have two fantastic interviews for you: The first is with Dr. Ben Mazer on the interplay between social media and news; the second is with Dr. Tem Bendapudi on whether Caplacizumab should
Source: SoundCloudCategories: Future of Medicine, Latest HeadlinesTweet
Recent evidence from brain MRIs suggests that silent cerebral #infarctions are not only common in survivors of #iTTP but are also strongly associated with impaired #cognition: https://t.co/nSzYCwnL9b